Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ARArvinas, Inc. logo

Arvinas, Inc. (ARVN)

NASDAQ Global Select · Currency in USD
$7.30 ▼ -0.42 (-5.44%)
At close: Oct 23, 4:00 PM ET. Market closed.
$7.35 ▲ +0.05 (+0.68%)
Pre-market: Oct 26, 7:23 AM ET

Summary

Previous Close
$7.72
Open
$7.70
Day's Range
$7.20 – $7.70
52 Week Range
$6.74 – $14.51
Volume
651,573
Avg. Volume
786,601
Market Cap
$471.00M
Beta (5Y Monthly)
1.81
PE Ratio (TTM)
38.42
EPS (TTM)
$0.14
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$14.17

Profile: Arvinas, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
246
CEO
Randy Teel

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.87 · Revenue est. $16.82M
DateEst.Actual
Aug 4, 2026-$0.37$2.58Beat
May 12, 2026-$0.95-$0.90Beat
Feb 24, 2026-$0.55-$1.10Miss
Nov 5, 2025-$0.75-$0.48Beat
Aug 6, 2025-$0.87-$0.84Beat
May 1, 2025-$0.86$1.14Beat

Analyst view

Consensus price target
$14.17 ▲ +94.1%
Range $10.00 – $20.00
Rating: Buy
Buy 73% · Hold 23% · Sell 4%

Get free alerts on ARVN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.